Jamp Pharma Corporation, in consultation with Health Canada, has voluntarily initiated a recall due to the potential presence of particulate matter in one (1) lot of Jamp-Methotrexate Injection USP 50 mg/2 mL. Presence of foreign particulate matter in vials of the affected lot could pose the following risks, if injected: local inflammation, phlebitis, allergic response, infection and/or embolization in the body. No complaints or adverse event reports have been received in relation to this product. Investigations related to controls for manufacturing sterile products at the manufacturing site are ongoing.
RecallTracker